protein-protein interaction

Live-cell assays using BRET offer a sensitive and scalable approach for studying small molecule and biologic interactions in real time.

As CROs and CDMOs expand their role in biopharma development and manufacturing, fast, accurate bioanalytic technologies remain critical to biotherapeutic affordability

Alzheimer's disease blood tests, FDA rejections, and more led the news this week. 

Discover how rapid viscosity and rheology testing with minimal sample volumes can help make better formulation decisions.

Discover how small molecule assemblies interact with protein aggregates to promote their breakdown  in neurodegenerative diseases.

Enzymes once viewed as rigid specialists are now being repurposed as modular tools, revealing latent chemical capabilities and enabling new approaches to molecule construction.

Scientists are using insights from viral hijacking to chemically reprogram E3 ligases, opening new opportunities in drug discovery.

Structural insights reveal how DCAF2 can be harnessed to target previously untouchable proteins for degradation.

A new class of small-molecule drugs could represent a therapeutic modality aimed at eliminating disease-causing proteins before they spread in the body.

Advances in screening and protein targeting are reviving interest in molecular glues as a strategy to tackle previously undruggable diseases.